Lymphoepithelioma-like carcinoma of the bladder: a case report
-
By
-
Ying Yu
-
Lei Zhang
-
July 8, 2026
-
Clinical Scorecard: Case Study of Lymphoepithelioma-like Carcinoma in the Bladder
At a Glance
| Category | Detail |
|---|
| Condition | Lymphoepithelioma-like carcinoma of the bladder (LELCB) |
| Key Mechanisms | Undifferentiated malignant tumor with histopathological features similar to lymphoepithelioma, not associated with EBV infection. |
| Target Population | Patients with bladder tumors, particularly rare cases of LELCB. |
| Care Setting | Urology and oncology departments in hospitals. |
Key Highlights
- LELCB accounts for less than 1.3% of all malignant bladder tumors.
- The main treatment methods include surgical resection and postoperative adjuvant therapy.
- The case study reports an 86-year-old female with recurrence after initial treatment.
- Histopathological examination revealed characteristic lymphoepithelioma-like morphology.
- No standardized treatment protocols or prognostic factors are currently established.
Guideline-Based Recommendations
Diagnosis
- Histopathological examination is essential for diagnosis.
Management
- Surgical resection followed by adjuvant chemotherapy is recommended.
Monitoring & Follow-up
- Regular follow-up is necessary to monitor for recurrence.
Risks
- Recurrence is possible, especially in older patients with comorbidities.
Patient & Prescribing Data
Older adults with bladder tumors.
Epirubicin hydrochloride is used for adjuvant chemotherapy.
Clinical Best Practices
- Conduct thorough imaging studies to assess tumor characteristics.
- Consider patient comorbidities when planning treatment.
- Ensure proper follow-up to detect recurrence early.
Related Resources & Content
